Arcadia Biosciences, Inc. (RKDA) — 8-K Filings

8-K Filings (18)

• Arcadia Biosciences Terminates Material Agreement — Dec 29, 2025 Risk: medium
  Arcadia Biosciences, Inc. filed an 8-K on December 29, 2025, reporting the termination of a material definitive agreement as of December 24, 2025. The filing al
• Arcadia Biosciences Files 8-K on Shareholder Vote Matters — Dec 23, 2025 Risk: low
  Arcadia Biosciences, Inc. filed an 8-K on December 23, 2025, reporting a submission of matters to a vote of security holders as of December 19, 2025. The compan
• Arcadia Biosciences Files 8-K on Shareholder Nominations & Events — Oct 24, 2025 Risk: low
  Arcadia Biosciences, Inc. filed an 8-K on October 24, 2025, reporting events as of October 22, 2025. The filing includes information on Shareholder Nominations
• Arcadia Biosciences Announces Board and Executive Compensation Changes — Aug 29, 2025 Risk: medium
  Arcadia Biosciences, Inc. announced on August 26, 2025, changes related to its board of directors and executive compensation. The filing details the departure o
• Arcadia Biosciences Files 8-K — May 16, 2025 Risk: low
  Arcadia Biosciences, Inc. filed an 8-K on May 16, 2025, reporting events as of May 14, 2025. The filing includes information on Regulation FD Disclosure, Other
• Arcadia Biosciences Files 8-K on Financials and Exhibits — May 8, 2025 Risk: low
  Arcadia Biosciences, Inc. filed an 8-K on May 8, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhib
• Arcadia Biosciences Enters Material Definitive Agreement — May 2, 2025 Risk: medium
  Arcadia Biosciences, Inc. announced on April 30, 2025, that it entered into a material definitive agreement. The company, incorporated in Delaware with its prin
• Arcadia Biosciences Files 8-K, Moves HQ to Dallas — Apr 3, 2025 Risk: low
  Arcadia Biosciences, Inc. reported a material definitive agreement on March 28, 2025. The company, incorporated in Delaware, filed an 8-K form with the SEC. The
• Arcadia Biosciences Files 8-K on Financials — Mar 20, 2025 Risk: low
  Arcadia Biosciences, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Arcadia Biosciences Files 8-K — Dec 11, 2024 Risk: low
  Arcadia Biosciences, Inc. filed an 8-K on December 11, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• Arcadia Biosciences Reports Material Agreement & Control Change — Dec 6, 2024 Risk: medium
  Arcadia Biosciences, Inc. announced on December 4, 2024, a material definitive agreement and a change in control. The company also reported the departure of dir
• Arcadia Biosciences Appoints New Directors, One Departs — Aug 7, 2024 Risk: low
  Arcadia Biosciences, Inc. announced on August 1, 2024, the departure of Director Michael McMillen and the appointment of two new directors, Dr. Robert H. Smith
• Arcadia Biosciences Appoints New CEO, Dr. Lowe — Jul 8, 2024 Risk: medium
  Arcadia Biosciences, Inc. announced on July 2, 2024, the appointment of Dr. David J. E. Lowe as Chief Executive Officer, succeeding Rajan S. Sajja. Dr. Lowe, wh
• Arcadia Biosciences Reports on Shareholder Vote — Jul 1, 2024 Risk: medium
  Arcadia Biosciences, Inc. filed an 8-K on July 1, 2024, reporting on a meeting held on June 25, 2024, where security holders voted on certain matters. The filin
• Arcadia Biosciences Acquires Full Control of Specialty Products Unit — May 20, 2024 Risk: low
  Arcadia Biosciences, Inc. announced on May 14, 2024, the completion of its acquisition of the remaining 50% interest in Arcadia Specialty Products, LLC from its
• Arcadia Biosciences Completes Full Acquisition of Specialty Products Unit — May 17, 2024 Risk: medium
  Arcadia Biosciences, Inc. announced on May 13, 2024, the completion of its acquisition of the remaining 50% interest in Arcadia Specialty Products, LLC from its
• Arcadia Biosciences Files 8-K on Financials — May 9, 2024 Risk: low
  Arcadia Biosciences, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Arcadia Biosciences Reports Officer & Director Changes, New Compensation — Feb 14, 2024 Risk: medium
  Arcadia Biosciences, Inc. (RKDA) filed an 8-K on February 14, 2024, reporting events that occurred on February 8, 2024. The filing indicates changes in its dire

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX